|
Genflow Biosciences PLC on Monday reported progress towards full protection of its longevity gene therapy platform. The company said the European Patent Office has recognised the patentability of claims of its Euro-PCT application, as it one of its European patents was officially published in the EPO on Wednesday last week. Genflow said the move marks a ‘major milestone’ in its intellectual property strategy. ‘The European publication number EP4630038 appeared in the bulletin, signifying that the patent application entered its final pre-grant phase under article 67(3) EPC,’ said the company. However, the company noted that further steps are still required for the patent to be formally granted. ‘This publication represents a major step toward securing European patent recognition for key elements of Genflow’s longevity gene therapy platform.’ noted Genflow. Shares in the London-based biotechnology firm were up 6.8% at 2.40 pence on Monday afternoon in London. ‘The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy. Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy platform and strengthens our strategic position for future partnerships and funding opportunities,’ said Chief Executive Eric Leire. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
